SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes.
Hae Kyung KimGeert Jan BiesselsMin Heui YuNamki HongYong-Ho LeeByung-Wan LeeEun Seok KangBong-Soo ChaEun Jig LeeMinyoung LeePublished in: Neurology (2024)
This study provides Class II evidence that SGLT2 antidiabetic drugs decrease the risk of dementia and PD in people with diabetes.